Key Takeaways
- •The race to develop the first convenient oral version of GLP-1 drugs has taken a decisive turn.
- •The implications are significant.
- •GLP-1 receptor agonists mimic a natural hormone called glucagon-like peptide-1, which is released after eating.
Novo Nordisk's Oral GLP-1 Lead Reshapes Investor Expectations
The race to develop the first convenient oral version of GLP-1 drugs has taken a decisive turn. Novo Nordisk has established a clear advantage in this specific segment, prompting investors to reconsider the long-held assumption that Eli Lilly dominates the GLP-1 market. A CNBC report published on May 4, 2026, highlights how this head start is reshaping competitive dynamics and forcing market watchers to adjust their strategies.
The implications are significant. While Eli Lilly has commanded attention with its injectable tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), the ability to deliver these drugs in pill form could expand the patient pool dramatically. Oral formulations remove needle aversion and simplify logistics, making them a potential gateway to broader adoption. Novo Nordisk's early progress in this area now challenges the prevailing narrative of Lilly's supremacy.
The Science Behind GLP-1 Pills
GLP-1 receptor agonists mimic a natural hormone called glucagon-like peptide-1, which is released after eating. This hormone stimulates insulin secretion, slows gastric emptying, and promotes satiety, effectively reducing appetite and blood glucose levels. Injectable versions like semaglutide (Ozempic, Wegovy) and tirzepatide have proven highly effective, but their mode of delivery remains a barrier for many patients.
Developing an oral GLP-1 drug is scientifically challenging. Peptides are large molecules that degrade rapidly in the acidic environment of the stomach and are poorly absorbed across the intestinal lining. Early attempts at oral GLP-1 drugs failed because bioavailability was too low to achieve therapeutic effect. Novo Nordisk overcame this with its proprietary absorption-enhancing technology using sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). This compound, co-formulated with semaglutide, protects the peptide from gastric degradation and facilitates absorption through the stomach lining.
The result is Rybelsus, an oral semaglutide tablet approved for type 2 diabetes since 2019. Rybelsus represents the first and only oral GLP-1 receptor agonist on the market. However, its bioavailability remains low: only about 1% of the oral dose reaches systemic circulation. Despite this limitation, the drug works well enough to achieve meaningful reductions in HbA1c and body weight. Novo Nordisk has since pursued higher-dose versions for obesity, including a 50 mg oral semaglutide tablet that showed promising weight loss in phase 3 trials (the OASIS program).
An oral pill fundamentally changes the treatment experience. Patients no longer need to refrigerate prefilled pens, learn injection techniques, or manage sharps disposal. The convenience could improve adherence, a critical factor in chronic conditions like obesity and type 2 diabetes. It also opens the door for patients who are unwilling or unable to use injectables.
Novo Nordisk's Head Start in the Pill Race
Novo Nordisk's lead in oral GLP-1 drugs is not accidental. The company invested heavily in formulation science long before competitors recognized the potential. By 2026, the company has accumulated years of real-world data from Rybelsus, giving it a deep understanding of dosing, side effects, and patient response.
The OASIS 1 trial, published in late 2024, evaluated a 50 mg daily oral semaglutide tablet in adults with obesity but without diabetes. After 68 weeks, participants lost an average of 15.1% of their body weight, compared to 2.4% with placebo. This efficacy rivals that of injectable semaglutide (Wegovy), which achieves around 15% weight loss. The result demonstrated that oral delivery can match injectable performance, at least at higher doses.
Novo Nordisk also has an edge in manufacturing. Producing oral peptides at scale requires specialized processes that few companies have mastered. The SNAC technology is proprietary and protected by patents. This creates a barrier to entry for competitors that cannot simply copy the formulation.
Of course, oral semaglutide has limitations. The drug must be taken on an empty stomach with only a small amount of water, and patients must wait at least 30 minutes before eating or drinking anything else. Missed doses or improper timing can reduce efficacy. Gastrointestinal side effects such as nausea, vomiting, and diarrhea are common, especially during dose escalation. Nonetheless, the convenience of a pill outweighs these drawbacks for many patients.
Eli Lilly's Position Under Scrutiny
Eli Lilly has dominated the GLP-1 sector with tirzepatide, a dual agonist that targets both GLP-1 and GIP receptors. In head-to-head trials, tirzepatide has shown superior weight loss and glycemic control compared to semaglutide. By early 2026, Lilly had captured a significant share of the injectable GLP-1 market, buoyed by strong demand and expanded manufacturing capacity.
However, Lilly is behind in oral GLP-1 development. Its candidate, orforglipron, is a non-peptide small molecule that acts as a GLP-1 receptor agonist. Because it is not a peptide, orforglipron avoids many of the bioavailability challenges that plague oral peptides. It can be taken with or without food and shows predictable absorption. In phase 2 trials, orforglipron produced weight loss of up to 14.7% at 36 weeks, comparable to semaglutide.
Orforglipron is currently in phase 3 trials, with regulatory submissions expected in late 2026 or 2027. That timeline puts Lilly at least a year behind Novo Nordisk's anticipated filing for oral semaglutide for obesity. Analysts note that this window gives Novo Nordisk time to build brand loyalty, establish prescribing habits, and capture early market share. Lilly will likely enter a market where standards have already been set.
The CNBC report underscores that investors are now reassessing Lilly's market position in light of this gap. Lilly's strength in injectables is undeniable, but the oral segment represents future growth. If oral formulations become the standard of care, Lilly's current dominance could erode. Some market watchers caution against overreaction, pointing out that Lilly's pipeline includes other promising candidates and that the obesity market is large enough to support multiple players.
Competition and Future Implications
The GLP-1 pill race extends beyond Novo Nordisk and Eli Lilly. Pfizer is developing lotiglipron (formerly PF-06882961), an oral small-molecule GLP-1 agonist, though its phase 2 results were mixed. Other companies like Viking Therapeutics and Amgen have compounds in earlier stages. However, Novo Nordisk's head start is substantial, and the company is leveraging its experience to optimize formulations for both diabetes and obesity.
Investors face a nuanced picture. Eli Lilly's injectable dominance remains profitable and growing, but the long-term trajectory depends on oral delivery. Novo Nordisk's early lead in pills may force Lilly to accelerate its timeline or pay penalties in market share. It may also push Lilly to invest more heavily in next-generation oral candidates or combination therapies.
The broader impact on public health could be significant. Oral GLP-1 drugs could lower barriers to treatment access, especially in resource-limited settings where injection equipment and cold chain storage are burdens. They could also reduce stigma associated with injectable obesity drugs. However, affordability remains a concern. Current list prices for GLP-1 drugs are high, and oral formulations are unlikely to be cheaper unless generic competition emerges later this decade.
Regulatory decisions will shape the competitive landscape. The U.S. Food and Drug Administration (FDA) will evaluate safety data from large cardiovascular outcomes trials for both oral semaglutide and orforglipron. Any labeling restrictions related to pancreatitis, gallbladder disease, or thyroid tumors could limit uptake.
Frequently Asked Questions
Q: How do oral GLP-1 pills work differently from injectable versions?
A: Oral GLP-1 pills use absorption-enhancing technology like SNAC to protect the peptide from stomach acid and facilitate uptake through the stomach lining. Injectable versions are absorbed directly into the bloodstream and bypass gastrointestinal degradation. Oral formulations require strict dosing conditions (empty stomach, waiting time), while injectables do not.
Q: What is the name of Novo Nordisk's oral GLP-1 pill?
A: Novo Nordisk markets oral semaglutide as Rybelsus for type 2 diabetes. The company is developing a higher-dose version (50 mg) for obesity, which is expected to be branded under a different name (likely a companion to Wegovy). Clinical trials refer to it as oral semaglutide.
Q: When might Eli Lilly's oral GLP-1 drug be available?
A: Eli Lilly's oral candidate, orforglipron, is in phase 3 trials. If successful, regulatory submissions could occur in late 2026 or 2027, with potential market launch in 2028 or later. This timeline places it behind Novo Nordisk's anticipated obesity approval for oral semaglutide.
Q: Is Novo Nordisk now the clear leader in GLP-1 drugs overall?
A: No. Eli Lilly remains dominant in injectable GLP-1 drugs due to tirzepatide's superior efficacy and strong sales. However, Novo Nordisk holds a clear lead in oral GLP-1 formulations, which could reshape future market dynamics. Both companies have competitive strengths in different segments.